30,580 Alzheimer's and dementia studies in plain English, each scored out of 100.
Early-stage DLB closely resembles PD in motor symptoms but has more neuropsychiatric non-motor symptoms compared to PD and overall non-motor symptoms than AD. 3 key findings →
Design: cross-sectional Participants: 107 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We identified 17 711 patients with PD or LBD. 5 key findings →
Design: case-control study Participants: 711 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
MEG 16-38Hz spectral power, particularly over parieto-occipital magnetometers, was significantly reduced in the AD progression group. 5 key findings →
Participants: 117 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
In PD‐SCD, baseline CSF Aβ42 is associated with cognitive progression. 5 key findings →
Design: cohort study Participants: 50 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The rate of reversion from MCI to normal cognition was 37.0% after 2 years and 32.9% after 12 years. 5 key findings →
Design: longitudinal study Participants: 1,262 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Cross-sectional studies suggest a limited relationship between accelerated epigenetic aging derived from epigenetic clocks, and Alzheimer's disease (AD) pathophysiology or risk. 3 key findings →
Design: cross-sectional Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Participants showed a significantly slower rate of cognitive decline than expected from the AD reference rate (p < 0.001), with many demonstrating stabilized ADAS-Cog scores during their respective treatment periods, ranging from 1 to 3 years. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A total of 101 FTD patients (64 ± 8 years, 53 men), 230 AD patients (65 ± 10 years, 84 men), and 173 CTR (59 ± 15 years, 67 men) were studied. 5 key findings →
Design: cross-sectional Participants: 101 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We included 3074 AD patients (mean age 78.1 years; 59.4% women), of whom 1028 used statins (79.6% simvastatin, 20.4% atorvastatin). 5 key findings →
Design: cross-sectional Participants: 3,074 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The final sample included 1196 cases (505 PD, 26 APD, 476 AD, 189 ALS) and 44,107 control subjects. 5 key findings →
Participants: 1,196 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The analysis included 121 521 participants (mean age: 55.7 years; 53.5% women), followed for a median of 10.9 years. 5 key findings →
Participants: 121 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Primary age-related tauopathy (PART) was proposed in 2014 as a neuropathological term to describe patients with Alzheimer's-type medial temporal lobe neurofibrillary degeneration in the absence of significant β-amyloid pathology. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
= 0.038) over time. Physical activity was associated with less synaptic dysfunction and cognitive activity with less synaptic dysfunction and lower amyloid burden over time, albeit effect sizes were small. 2 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 6321 participants (mean [SE] age, 56.1 [0.18] years at visit 1; n = 4077 women [57.8%]) were included. 5 key findings →
Design: cohort study Participants: 4,077 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The optimized XGBoost model demonstrated superior performance, achieving an AUC of 0.85. 5 key findings →
Participants: 17,000 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Delirium is a common and serious clinical condition that is associated with several adverse, and sometimes permanent outcomes. 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The 3D-CAM-S severity scores correlated with DRS, delirium duration, and biomarkers of delirium. 1 key finding →
Design: cohort study Participants: 177 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Mean age was 83.5 years (delirium 78.7 vs non-delirium 88.4); 13/20 were female; 17/20 had premorbid cognitive decline/impairment or dementia. 5 key findings →
Design: case-control study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 24,043 patients were included, with 2,662 (11.07%) in the ND group. 5 key findings →
Design: cohort study Participants: 24,043 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In adjusted analyses, the rate of first ACP conversation for persons with organ failure was the lowest (IRR 0.70 (95% CI 0.68 to 0.73)). 5 key findings →
Design: longitudinal study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Five WMH clusters emerged. Compared to those with low WMH burden, participants in the mild occipital and high parieto-occipital clusters had faster memory decline; mild fronto-parietal and high parieto-occipital clusters showed faster executive decline; and mild and high fronto-parietal and high parieto-occipital clusters had faster language decline. 5 key findings →
Design: longitudinal study Participants: 1,047 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
This validated nomogram incorporating clinical, biochemical, and neuroimaging biomarkers provides a robust tool for individualized PSCIND risk assessment in first-ever MIS patients, with potential to guide targeted interventions and cognitive monitoring. 2 key findings →
Design: cohort study Participants: 137 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Overall, 392 patients were enrolled in HARMONY; 49 patients with PDD and 27 patients with DLB were included in the open-label safety analysis, of whom 46 met response criteria and were randomized to receive pimavanserin (n = 22) or placebo (n = 24) during the double-blind period. 4 key findings →
Design: phase-3-trial Participants: 76 Evidence: early
Full summary, score breakdown and related studies → Original source Free full text
This approach offers a sensitive method for identifying individuals at high risk for AD-related cognitive decline. 1 key finding →
Participants: 954 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Plasma phosphorylated threonine 181 of tau (pTau181) and amyloid beta (Aβ) are biomarkers for differential diagnosis and preclinical detection of Alzheimer disease (AD). 2 key findings →
Participants: 2,086 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 30,580 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 30,580 records, built mostly from automated pulls of Europe PMC (64.7% of the library) and OpenAlex (16.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,037 records (3.4% of the library) are not peer-reviewed — 964 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events